FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex wins FDA approval for long-awaited non-opioid painkiller
Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
Seeking Alpha7d
VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
American Association of Individual Investors9d
Which Is a Better Investment, Natera, Inc. or Vertex Pharmaceuticals Incorporated Stock?
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
MedCity News8d
Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds
A novel Vertex Pharmaceuticals drug that takes a new ... such as aches following an injury or a surgical procedure. The Boston-based company’s new drug, a twice-daily pill known in development ...
FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
Wall Street Journal8d
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals VRTX5.31%increase ... received Food and Drug Administration approval. The Boston company’s stock rose 4.3%, to $457.25, after hours Thursday.
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Bank of America Securities Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...